{
  "id": 13257481,
  "title": "Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock",
  "url": "https://urgent.news/2026/10/09/pacira-biosciences-senior-vice-president-lauren-riker-sells-217-920",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T23:31:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pacira-biosciences-senior-vice-president-lauren-riker-sells-217920-in-stock-93CH-4941838"
  },
  "original_language": "en",
  "account": "Pacira BioSciences senior vice president Lauren Riker sold 6,000 shares of the company's stock in early October 2026. The transaction, conducted under a pre-arranged trading plan, netted her $217,920. The shares were disposed of at $36.32 each, close to the stock's 52-week peak of $36.46. Over the past week, the stock price has risen by 44%, while its value has skyrocketed by 57% in the last year. This move was made following the exercise of stock options, which Ms. Riker acquired through her employment, valued at $194,100. She now holds a total of 62,284.242 shares of Pacira BioSciences common stock. InvestingPro analysts view the stock as potentially undervalued, assigning it a Piotroski Score of 9, indicating robust financial health. The company's revenue grew by 6% in the second quarter, reaching $192.4 million, slightly exceeding expectations. This growth follows the successful performance of the company's principal products and a significant coverage win with a payer. In a separate development, Viatris acquired Pacira Pharmaceuticals for $1.65 billion, leading to a downgrade of Pacira's stock from 'Buy' to 'Hold' by Jefferies, with a price target of $36.00. Despite this, Oppenheimer maintains an 'Outperform' rating and a price target of $32.00, citing a positive outlook for Exparel as it enters a growth phase. These events shed light on the shifting market landscape surrounding Pacira BioSciences.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}